Pharmaceutical

SN Bioscience’s nano-cancer therapy wins orphan drug designation

The FDA grants SN Bioscience’s nano-therapy SNB-101 an orphan drug designation for small cell lung cancer.

Jul 21, 2023 - 20:00
SN Bioscience’s nano-cancer therapy wins orphan drug designation
The FDA grants SN Bioscience’s nano-therapy SNB-101 an orphan drug designation for small cell lung cancer.
Read the original article

Tags:

Previous Article

How orphan designated drugs private equity performed in the pharmaceutical indus...

Next Article

Immunotherapy Insights: Oncolytic viruses struggle to find a spot in a crowded f...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Medical device lobby says it’s tired of waiting on Medicare to cover breakthrough devices

STAT+: Medical device lobby says it’s tired of waiting ...

Mar 2, 2024

EMA accepts Deciphera’s MAA cell tumour treatment for review

EMA accepts Deciphera’s MAA cell tumour treatment for r...

Jul 20, 2024

STAT+: Researchers devise new strategies to overcome a key CRISPR flaw

STAT+: Researchers devise new strategies to overcome a ...

Mar 22, 2023